Literature DB >> 17512164

The management of Takayasu's arteritis: personal experience.

Stefano de Franciscis1, Raffaele Serra, Alessandro Luongo, Giuseppe Sabino, Alessandro Puzziello.   

Abstract

Takayasu's arteritis is a chronic vasculitis mainly involving the aorta and its main branches. Almost all patients have ischemic disorders of the involved vessels. Treatment is nowadays controversial. Relapses are frequent. In the present study, we elucidate the long-term outcomes of our patients with Takayasu's arteritis. Between November 1993 and October 2003, 10 patients with Takayasu's disease were treated. All patients underwent medical treatment (corticosteroid for 7 months, cyclophosphamide for 3 months, and methotrexate for 12 months). Two patients stopped treatment with methotrexate when renal failure occurred. Four patients underwent a surgical procedure. During treatment, erythrocyte sedimentation rate and C-reactive protein concentrations were determined as indexes of inflammatory activity and treatment responsiveness. Four out of eight patients (50%) who underwent the full treatment with methotrexate had no relapse of the disease. The other four patients (50%) had relapse of the disease but had a better response to new corticosteroid treatment. The two patients who stopped methotrexate treatment died from complications of Takayasu's arteritis. In our personal experience, long-term treatment with methotrexate demonstrated a certain efficacy in avoiding relapse, maintaining stability of results, and amplifying the effects of steroid in patients with relapse.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17512164     DOI: 10.1016/j.avsg.2007.03.021

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  8 in total

1.  Combined medical, surgical and endovascular treatment of a giant cell arteritis case manifesting as upper limbs acute ischemia.

Authors:  Stefano de Franciscis; Giuseppe Roscitano; Raffaele Serra; Gianluca Buffone; Attilio Cotroneo; Andrea de Franciscis; Diego Mastrangelo; Francesco Spinelli
Journal:  Int J Surg Case Rep       Date:  2011-02-15

2.  Analysis of predictive factors for treatment resistance and disease relapse in Takayasu's arteritis.

Authors:  Ying Sun; Lili Ma; Huiyong Chen; Xiufang Kong; Peng Lv; Xiaomin Dai; Zongfei Ji; Chengde Yang; Shengming Dai; Lijun Wu; Yaohong Zou; Jiang Lin; Hongcheng Shi; Qiang Yu; Lindi Jiang
Journal:  Clin Rheumatol       Date:  2018-04-23       Impact factor: 2.980

3.  A Case of Takayasu's Arteritis with Total Occlusion of the Abdominal Aorta Treated Only with Oral Medication for More Than 40 Years.

Authors:  Kenichi Aizawa; Jun Fujii; Yoshinori Seko
Journal:  Ann Vasc Dis       Date:  2015-05-26

4.  Visceral Artery Interventions in Takayasu's Arteritis.

Authors:  Sanjiv Sharma; Ashish Gupta
Journal:  Semin Intervent Radiol       Date:  2009-09       Impact factor: 1.513

5.  Variations in the clinical practice of physicians managing Takayasu arteritis: a nationwide survey.

Authors:  Lillian Barra; Patrick Liang; Susanne M Benseler; David A Cabral; Aurore Fifi-Mah; Yueyang Li; Nataliya Milman; Marinka Twilt; Elaine Yacyshyn; Christian Pagnoux
Journal:  Open Access Rheumatol       Date:  2017-05-05

Review 6.  Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis-a systematic review and meta-analysis.

Authors:  Durga Prasanna Misra; Upendra Rathore; Pallavi Patro; Vikas Agarwal; Aman Sharma
Journal:  Clin Rheumatol       Date:  2021-05-01       Impact factor: 3.650

7.  Effects of glucocorticoids and tumor necrosis factor-alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis.

Authors:  Raffaele Serra; Raffaele Grande; Gianluca Buffone; Edoardo Scarcello; Fabio Tripodi; Pierandrea Rende; Luca Gallelli; Stefano de Franciscis
Journal:  J Pharmacol Pharmacother       Date:  2014-07

8.  Efficacy and safety of leflunomide versus cyclophosphamide for initial-onset Takayasu arteritis: a prospective cohort study.

Authors:  Sun Ying; Cui Xiaomeng; Dai Xiaomin; Lin Jiang; Lv Peng; Ma Lili; Chen Rongyi; Ji Zongfei; Chen Huiyong; Jiang Lindi
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-06-02       Impact factor: 5.346

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.